Cardiovascular Diagnostics: Key Developments in Technologies and Markets addresses the latest trends and developments in cardiovascular imaging and in vitro diagnostic techniques that will impact the market and the delivery of healthcare.
Cardiovascular diseases continue to be an enormous medical and cost burden on the health care system. As the rapidly aging population drives an increase in the incidence and prevalence of heart disease, the need for early detection and intervention will escalate dramatically. Cardiovascular Diagnostics: Key Developments in Technologies and Markets describes how the evolution of imaging technologies and discovery of new biomarkers is leading to continuous improvement in the ability to diagnose disease, monitor drug treatment, and identify patients at risk for cardiovascular events, such as heart attack and stroke.
The following market trends and developments, as well as the companies competing in each area, are evaluated:
- A high clinical need exists for non-invasive angiography procedures to assess coronary artery blockages. The report evaluates new CT scan technology and its potential to deliver billions of dollars in savings to the health care system along with a lower risk of complications for the patient.
- Emerging cardiovascular biomarkers that will allow for better detection of patients at risk for developing coronary artery disease, including C-Reactive Protein, as well as a number of different inflammatory and ischemia biomarkers that are under investigation for faster diagnosis of myocardial infarction and to rule out acute coronary syndrome in patients presenting with chest pain.
- New radiopharmaceuticals agents being developed for cardiovascular nuclear medicine that promise to improve diagnosis.
- Advances in magnetic resonance (MR) imaging and other imaging modalities used in cardiovascular diagnostics.
- Early-stage developments in imaging unstable or ruptured plaque deposits in arteries.
- The emerging trend of cardio-theranostics, the pairing of a laboratory test with a cardiovascular drug.